Clinical trials: Efavirenz
HIV Infections
Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients
The purpose of this study is to see if a novel 4-drug anti-HIV combination can suppress the growth of HIV in patients infected with the virus.
- Trial name
- NCT00038220
- Testing
- Lopinavir/ritonavir, Efavirenz, Lamivudine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Abbott
HIV Infections
A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs
The purpose of this study is to compare the safety and effectiveness of emtricitabine and stavudine when given with didanosine plus efavirenz to HIV-infected patients.
- Trial name
- NCT00006208
- Testing
- Efavirenz, Emtricitabine, Stavudine
- Where
- 63 sites in United States, Argentina and 4 more
- Sponsor
- Triangle Pharmaceuticals
HIV Infections
Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment
The purpose of this study is to see how effective and safe it is to give 1 of the 3 following treatments to patients who may not have received anti-HIV treatment: 1) lamivudine (3TC)/abacavir (ABC)/stavudine (d4T); 2)…
- Trial name
- NCT00005017
- Testing
- Ritonavir, Abacavir sulfate, Amprenavir
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Glaxo Wellcome
Infections, Human Immunodeficiency Virus and Herpesviridae
GSK1349572 Drug Interaction Study With Efavirenz
GSK1349572 is an integrase inhibitor that is currently in Phase 2 clinical trials for the treatment of HIV infection. As GSK1349572 development progresses, it may be dosed with non-nucleoside HIV reverse transcriptase inhibitors…
- Trial name
- NCT01098526
- Testing
- GSK1349572, Efavirenz
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infection
A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy
This is a 48-week study to evaluate the safety and efficacy of a new tablet formulation containing two FDA-approved drugs in HIV-infected patients who have not received prior therapy.
- Trial name
- NCT00053638
- Testing
- efavirenz, tenofovir, abacavir/lamivudine
- Where
- 58 sites in United States
- Volunteers
- 345 people
- Sponsor
- GlaxoSmithKline
HIV/AIDS
Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects
The purpose of this study is to determine whether multiple doses of Efavirenz has an effect on the QTc interval (corrected by Fridericia) in CYP2B6 *1/*6 and *6/*6 healthy subjects.
- Trial name
- NCT02164812
- Testing
- Moxifloxacin, Efavirenz
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Malaria
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz
This study assessed the effect of multiple doses of a moderate inducer of cytochrome P450 (CYP) 3A4 (efavirenz) on the pharmacokinetics (PK) of ganaplacide and lumefantrine combination.
- Trial name
- NCT05330273
- Testing
- Ganaplacide, Lumefantrine, Efavirenz
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
HIV Infections
Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients
The purpose of this study is to compare the safety and effectiveness of 2 forms of stavudine (d4T). One form is taken once a day (extended release) and the other form is taken twice a day (immediate release).
- Trial name
- NCT00005918
- Testing
- Efavirenz, Lamivudine, Stavudine
- Where
- 77 sites in United States, Argentina and 14 more
- Volunteers
- 730 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
A Study to Compare Two Anti-HIV Drug Combinations
The purpose of this study is to compare 2 anti-HIV drug combinations.
- Trial name
- NCT00002447
- Testing
- Ritonavir, Efavirenz, Saquinavir
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 146 people
- Sponsor
- Hoffmann-La Roche
Healthy Subjects, Drug-drug Interaction
A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants
This drug-drug interaction (DDI) study has been designed to investigate the effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of quizartinib and its major circulating active metabolite AC886.
- Conditions
- Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, Quizartinib
- Trial name
- NCT04459598
- Testing
- Efavirenz, Quizartinib
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo Co., Ltd.
HIV Infections
Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants
Elvucitabine, a novel nucleoside analog, is being studied as a treatment for participants with human immunodeficiency virus (HIV)-1.
- Trial name
- NCT00350272
- Testing
- Elvucitabine, Lamivudine, Tenofovir
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 76 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
HIV Infections, AIDS
DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy
The purpose of this study is to evaluate whether a therapy with an all once daily regimen of efavirenz (EFV), didanosine (ddI)-EC and lamivudine (3TC) leads to improved outcomes, as measured by viral load, CD4 counts, adherence…
- Trial name
- NCT00116415
- Testing
- efavirenz; didanosine EC; lamivudine
- Where
- 9 sites in United States
- Volunteers
- 65 people
- Sponsor
- Bristol-Myers Squibb
Infection, Human Immunodeficiency Virus I, HIV Infection
KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects
Recently, the fixed-dose combinations (FDC) KIVEXA™ (abacavir/lamivudine) and TRUVADA (tenofovir disoproxil fumarate/emtricitabine) have facilitated the usage of once-daily regimens.
- Trial name
- ASSERT (NCT00549198)
- Testing
- Abacavir/lamivudine and efavirenz, Tenofovir/Emtricitabine and efavirenz
- Where
- 68 sites in Austria, Belgium and 11 more
- Volunteers
- 392 people
- Sponsor
- GlaxoSmithKline
Healthy
A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)
The goal of the study is to learn what happens to levels of nemtabrutinib (MK-1026) in a healthy person's body over time. Researchers will compare what happens to nemtabrutinib in the body when it is given with or without another…
- Trial name
- NCT06698016
- Testing
- Nemtabrutinib, Efavirenz
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients
The purpose of this study is to compare the safety and effectiveness of three anti-HIV drug combinations. The three combinations are: (1) efavirenz (DMP 266) plus indinavir; (2) DMP 266 plus zidovudine (ZDV) plus lamivudine…
- Trial name
- NCT00002410
- Testing
- Indinavir sulfate, Lamivudine, Zidovudine
- Where
- 41 sites in United States, Puerto Rico
- Sponsor
- Dupont Merck
HIV Infections, Protease Inhibitor
Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects
The purpose of this study is to assess the exposure of Atazanavir 400 mg with Ritonavir 100 mg and with Efavirenz 600 mg compared to Atazanavir 300 mg with 100 mg without Efavirenz in Healthy Subjects
- Trial name
- NCT00357188
- Testing
- Atazanavir Sulphate + Ritonavir, Atazanavir Sulphate + Ritonavir + Efavirenz
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
AIDS
To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine
To assess compliance of once daily dosing to assess their benefits in terms of potency and safety as well as their impact on adherence and quality of life.
- Trial name
- NCT00207168
- Testing
- Compliance
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
HIV-1, Central Nervous System
Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)
This study aims to evaluate a switch from fixed dose combination (FDC) treatment with ATRIPLA^TM for 12 weeks prior to screening to FDC treatment with Doravirine, Tenofovir, Lamivudine (MK-1439A) in virologically-suppressed…
- Trial name
- NCT02652260
- Testing
- Doravirine, Tenofovir, Lamivudine - Blinded, Doravirine, Tenofovir, Lamivudine - Open-Label, ATRIPLA^TM
- Volunteers
- 86 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen
The purpose of this study is to demonstrate that virologically controlled HIV-infected individuals can successfully switch from a protease inhibitor (PI)-based regimen to an efavirenz-based regimen while maintaining virologic…
- Trial name
- NCT00135382
- Testing
- Videx EC, Epivir, Sustiva
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 254 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
The purpose of this study is to see if it is safe and effective to give efavirenz plus stavudine plus lamivudine to patients who have never taken anti-HIV drugs.
- Trial name
- NCT00002227
- Testing
- Efavirenz, Lamivudine, Stavudine
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Dupont Merck